Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

[1]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[2]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[3]  B. Tombal,et al.  Prostate cancer: STAMPEDE, LATITUDE and Fernand Labrie's legacy , 2017, Nature Reviews Urology.

[4]  H. Scher,et al.  Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone , 2017, Clinical Cancer Research.

[5]  N. Agarwal,et al.  Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Antonarakis,et al.  Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort , 2016, European urology.

[7]  T. Tammela,et al.  Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. , 2016, European urology.

[8]  E. Antonarakis,et al.  Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer , 2016, Current Urology Reports.

[9]  A. Villers,et al.  Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. , 2016, The Lancet. Oncology.

[10]  E. Antonarakis,et al.  Androgen pathway resistance in prostate cancer and therapeutic implications , 2015, Expert opinion on pharmacotherapy.

[11]  P. Nelson.  Targeting the androgen receptor in prostate cancer--a resilient foe. , 2014, The New England journal of medicine.

[12]  T. Tammela,et al.  Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. , 2014, The Lancet. Oncology.

[13]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[14]  H. Xu,et al.  Androgen receptor: structure, role in prostate cancer and drug discovery , 2014, Acta Pharmacologica Sinica.

[15]  S. Larson,et al.  Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  V. Luu‐The.  Assessment of steroidogenesis and steroidogenic enzyme functions , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[18]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[19]  M. Wirth,et al.  Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years , 2010, BJU international.

[20]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[21]  F. Labrie,et al.  Androgen biosynthetic pathways in the human prostate. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[22]  F. Labrie,et al.  Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? , 2002, Urology.

[23]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[24]  I. Melezínek,et al.  Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. , 2000, The Journal of urology.

[25]  J. Simard,et al.  Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. , 2000, Journal of molecular endocrinology.

[26]  D. Ornstein,et al.  Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer , 1999, BJU international.

[27]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[28]  T. Tammela,et al.  A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer , 1998, European Urology.

[29]  M. Koutsilieris,et al.  Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. , 1993, The Journal of urology.

[30]  M. Costantini,et al.  Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. , 1991, The Journal of urology.

[31]  R. Neri.  Pharmacology and pharmacokinetics of flutamide. , 1989, Urology.

[32]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[33]  F. Labrie,et al.  Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. , 1988, Journal of steroid biochemistry.

[34]  R. Sylvester,et al.  Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. , 1986, The Journal of urology.

[35]  P. Kelly,et al.  Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. , 1980, International journal of fertility.

[36]  D. Albert,et al.  SCH 13521 in the treatment of advanced carcinoma of the prostate. , 1974, The Journal of urology.

[37]  W. Mainwaring.  A soluble androgen receptor in the cytoplasm of rat prostate. , 1969, The Journal of endocrinology.

[38]  N. Bruchovsky,et al.  The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. , 1968, The Journal of biological chemistry.

[39]  S. Liao,et al.  Selective Retention of Dihydrotestosterone by Prostatic Nuclei , 1968, Nature.

[40]  N. Bruchovsky,et al.  The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. , 1968, The Journal of biological chemistry.

[41]  R. Neri,et al.  Biological studies on an anti-androgen (SH 714). , 1967, European journal of pharmacology.

[42]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. , 1941, CA: a cancer journal for clinicians.

[43]  A. Alva,et al.  The changing natural history of metastatic prostate cancer. , 2013, Cancer journal.

[44]  E. Crawford.  Hormonal Therapy in Prostate Cancer: Historical Approaches , 2004 .

[45]  L. Fioretto,et al.  Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. , 1991, Cancer detection and prevention.

[46]  M. Namer,et al.  Anandron (RU 23908) Associated with Orchiectomy in Stage D Prostate Cancer Preliminary Results of a Randomized, Double‐Blind Study , 1988, American journal of clinical oncology.

[47]  F. Labrie,et al.  Complete androgen blockade for the treatment of prostate cancer. , 1985, Important advances in oncology.

[48]  F. Labrie,et al.  New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens , 1983, The Prostate.

[49]  F. Labrie,et al.  New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. , 1982, Clinical and investigative medicine. Medecine clinique et experimentale.

[50]  A. L. Tharp,et al.  Synthesis and bacteriostatic activity of some nitrotrifluoromethylanilides. , 1967, Journal of medicinal chemistry.